Douglas Lyles to Interferon-beta
This is a "connection" page, showing publications Douglas Lyles has written about Interferon-beta.
Connection Strength
0.445
-
Ahmed M, McKenzie MO, Puckett S, Hojnacki M, Poliquin L, Lyles DS. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol. 2003 Apr; 77(8):4646-57.
Score: 0.227
-
Westcott MM, Liu J, Rajani K, D'Agostino R, Lyles DS, Porosnicu M. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis. J Virol. 2015 Aug; 89(15):7944-54.
Score: 0.132
-
Blackham AU, Northrup SA, Willingham M, Sirintrapun J, Russell GB, Lyles DS, Stewart JH. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma. J Surg Res. 2014 Apr; 187(2):412-26.
Score: 0.030
-
Randle RW, Northrup SA, Sirintrapun SJ, Lyles DS, Stewart JH. Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors. Surgery. 2013 Dec; 154(6):1323-29; discussion 1329-30.
Score: 0.029
-
Blackham AU, Northrup SA, Willingham M, D'Agostino RB, Lyles DS, Stewart JH. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery. 2013 Mar; 153(3):333-43.
Score: 0.028